EDTA chelation therapy in chronic degenerative disease. Olszewer E, Carter JP. Med Hypotheses. 1988 Sep;27(1):41-9.

Hyperbaric Oxygen Clinic, Sao Paulo, Brazil.A retrospective analysis of treatment results from 2870 patients, with various chronic degenerative and age-associated diseases, who were treated with di-sodium magnesium EDTA chelation therapy, suggests that the case against EDTA Chelation Therapy should be re-opened. Using qualitative but never-the-less standardized criteria for improvement, our analysis shows that EDTA Chelation Therapy resulted in "marked" improvement in 76.89% and "good" improvement in 16.56% of patients with ischemic heart disease; also, "marked" improvement in 91% and "good" improvement in 7.6% of patients with peripheral vascular disease and intermittent claudication. In a group of patients with cerebro-vascular and other degenerative cerebral diseases, 24% had "marked" improvement, and 30% had "good" improvement. Of four patients with scleroderma, three had "marked" improvement and one had "good" improvement. Seventy-five percent of all of the patients had "marked" improvement in "geriatric symptomatology of vascular origin". The authors recommend renewed study of EDTA Chelation Therapy. The possibility of a "tomato effect", i.e., a drug which works, but the majority of physicians believe that it doesn't work, needs to be ruled out. A favorable climate needs to be created, in which FDA-approved studies of its usefulness in treating peripheral vascular disease can take place.



Animal Studies(cardiovascular):

The effects of magnesium sulphate and EDTA in the hypercholesterolaemic rabbit. Diabetes Obes Metab. 2001 Dec;3(6):417-22.

Evans DA, Tariq M, Sujata B, McCann G, Sobki S.Riyadh Armed Forces Hospital, Riyadh, Kingdom of Saudi Arabia Manfouha Central Hospital Riyadh, Kingdom of Saudi Arabia.Numerous clinical reports suggest the beneficial effects of chelation therapy for the treatment of atherosclerosis. The purpose of this present study was to examine the prophylactic and therapeutic effects of chelation liquid (CHL) in experimental atherosclerosis. Twenty New Zealand white rabbits were fed a 1% cholesterol-supplemented diet for 45 days. In the prophylactic phase of the study subcutaneous 300 mg EDTA + 500 mg magnesium sulphate (MgSO4) injections (five rabbits) and isotonic saline (five rabbits) were given to test and control groups, respectively, along with cholesterol rich diet. The CHL treatment ameliorated the rise of serum cholesterol and serum triglyceride concentrations, lowered serum calcium concentrations and reduced the aortic atheroma.


Alternative Medicine

Integrative cardiac revitalization: bypass surgery, angioplasty, and chelation. Benefits, risks, and limitations. Kidd PM. Altern Med Rev. 1998 Feb;3(1):4-17.

University of California at Berkeley, USA.Coronary artery disease (CAD) is still the main cause of premature death in the industrialized world. The revascularization modalities, bypass surgery and angioplasty, when successful provide restored blood flow to the myocardium. Bypass remains the most proven means for managing more severe cases of CAD, namely triple vessel disease with or without complications, while angioplasty works best for cases of single or double vessel disease with minimal complications. Both types of intervention partially relieve angina as they clear arterial blockage. Both save lives to an extent greater than medication alone. However, both are limited to being palliative since they fail to treat the underlying atherosclerotic occlusive process. EDTA chelation therapy appears to achieve revitalization of the myocardium, and is a viable alternative or adjunct to revascularization. Fish oils are now proven to help revitalize vessel wall endothelia and to partially reverse atherosclerotic damage. Being safe and having proven benefits, chelation therapy and fish oils can be integrated together with nutrients, lifestyle-dietary revision, exercise, and medications as necessary, into a cardiovascular revitalization strategy. Cardiovascular revitalization would be highly cost-effective and procedurally compatible with the revascularization modalities, while extending beyond revascularization to halt atherosclerotic progression, restore cardiac functionality, extend survival, and improve quality of life.**********************************************

EDTA chelation therapy should be more commonly used in the treatment of vascular disease. Chappell LT. Altern Ther Health Med. 1995 May;1(2):53-7.

Wright State School of Medicine, USA.EDTA chelation therapy is safe, effective, and more economical than commonly used surgical treatments for vascular disease. This article includes evidence of effectiveness, mechanisms of action of EDTA, a discussion of studies that have been done regarding the therapy, and some brief case reports. The conclusion is that EDTA chelation therapy should be a therapeutic option for vascular disease, either by itself or in conjunction with standard protocols


To Evaluate the use of Edta, Calcium Chelating, in the Coronary Heart Disease Treatment; Pea Quian, Yamil; Batista C, Juan F; Coca Marco, A; Stusser, Rodolfo; Ruibal L, Antonio; Rochela V, Luis M.

Center for Clinical Research, Havana, Cuba

SUMMARY Introduction: Last decades, it has been to achieve results in coronary heart disease treatments with calcium chelating. The EDTA is the more used drug in the world. Some works had demonstrated that, the EDTA administered by means of arterial infusion acts over calcium arterial deposit, which they are common component of the complicated ateroma plate, achieving the reduction of extent of it. Objectives: To study the existence or not of remission of the coronary heart disease after the treatment with EDTA.Material and Methods: Twelve patients were included, eleven men and one woman. All of them were determined risk factors, kind of coronary artery disease and treatment. All patients were study by: rest electrocardiogram, ergometric evaluation and heart perfusion SPECT. They were subjected to treatment, it consist of the administration through arterial infusion of EDTA (600 mg/Kg/min) diluted in 300 ml of dextrose (5%) with a duration from 4 to 5 hours during 25 sessions. Finished the treatment, all patients were evaluated again according to the clinical manifestations, treatment, electrocardiogram and the heart perfusion SPECT results.Results: Three patients had significant improvements, in the clinic and heart perfusion (an increase more than 10% of perfusion for studied segment). Two patients referred to feel clinically better and showed non-significant improvements in the heart perfusion (an increase smaller than 10% of the perfusion for segment). Six patients stayed without changes and only one patient presented non-significant worsening.


The value of chelation therapy is supported by a long list of formal, clinical research studies involving tens of thousands of patients. Dr. Norman Clarke did the first clinical studies, in which his patients were relieved of cardiac chest pain, and some abnormal electrocardiograms returned to normal. [5,6,7] Since then, it has been studied and positive effects were demonstrated again and again in groups of patients with circulation problems. [8-27]

A particularly important effect of chelation therapy is on the tiny arteries that deliver blood to areas such as the eye, the brain, and the skin. This is known as microcirculation, which is essential to the health of every tissue in the body. In diabetes, much of the damage is due to obstruction to microcirculation. Amongst the problems more common to diabetics is poor circulation to the legs and feet, along with the possibility of developing gangrene. There are published sequential photographs showing the reversal of gangrene in the toes of patients receiving chelation therapy. [25] The overall success rate in problems with circulation, as measured from many different scientific studies, is in the range of 85-90%. [26]

5. Clarke NE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci 1956; 232:654-66.

6. Clarke NE. Atherosclerosis, occlusive vascular disease, and EDTA. Am J Cardiol 1960; 6:233.

7.Clarke NE et al. Treatment of occlusive vascular disease with disodium EDTA. Am J Med Sci 1960; 239:732-44.

8. Meltzer LE et al. The treatment of coronary artery disease with disodium EDTA. In Seven MJ (ed): Metal-Binding in Medicine, Philadelphia: Lippincott; 1960.

9. Kitchell JR et al. Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis 1961; 3:338-49.

10.Boyle AJ et al. Chelation therapy in circulatory and sclerosing diseases. Fed Proc 1961 Sep; 20(3)Pt 2:243-52.

11. Kitchell JR et al. The treatment of coronary artery disease with disodium EDTA - a reappraisal. Am J Cardiol 1963; 11:501-6. 12.

Lamar CP. Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology 1964; 15:379-95.

13. Lamar CP. Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatrics Soc 1966; 15:272-94.

14. Casdorph HR. EDTA chelation therapy, efficacy in arteriosclerotic heart disease. J Holistic Med. 1981; 3:53-9.

15. Casdorph HR. EDTA chelation therapy II, efficacy in brain disorders. J Holistic Med. 1981; 3:101-17.

16. Robinson DM. Chelation therapy. N Z Med J 1982; 95:750.

17. McDonagh EW. An oculocerebrovasculometric analysis of improvement in arterial stenosis following EDTA chelation therapy. J Holistic Med. 1982; 4:21-3.

18. McDonagh EW. Effect of EDTA chelation therapy plus multi-vitamin trace mineral supplementation upon vascular dynamics. J Holistic Med. 1985; 7:16-22.

19. Olszwer JP. EDTA chelation therapy: a retrospective study of 2,870 patients. Med. Hypothesis 1988; 27:41-9.

20. Rudolph CJ. Effect of EDTA chelation and supportive multivitamin/trace mineral supplementation on carotid circulation: case report. J Adv Med. 1990; 3:1, Spring: 5-11.

21. Olszwer E. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Nat Med Assn 1990; 82;3.

22. Rudolph CJ. A non-surgical approach to obstructive carotid stenosis using EDTA chelation. J Adv Med 1991; 4; 3:157-68.

23. Hancke C. Benefits of EDTA chelation therapy in arteriosclerosis: a retrospective study of 470 patients. J Adv Med 1993; 6; 3:161-71.

24. McDonagh EW. Non-invasive treatment for sequelae of failed coronary blood circulation. J Neuro Ortho Med Surg 1993; 14:169-73.

25. Casdorph HR, Farr CH. EDTA chelation therapy: treatment of peripheral arterial occlusion, an alternative to amputation. J Adv Med 1989; 2; 1,2:170-80.

26. Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvements in cardiovascular function meta-analysis. J Adv Med 1993; 6;3:139-60.

27. Hancke C, Flytlie K. Benefits of EDTA chelation therapy in arteriosclerosis. J Adv Med 1993; 6; 3:161-71.


Guldager B, Jelnes R, Jorgensen S, et al. EDTA treatment of intermittent claudication - a double-blind, placebo-controlled study. J Intern Med. 1992;231:261-267.

Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg. 1991;162:122-125.

van Rij A, Solomon C, Packer S, Hopkins W. Chelation therapy for intermittent claudication: a double-blind, randomized, controlled trial. Circulation. 1991;162:122-125.


Scientific Rationale for EDTA Chelation Therapy Mechanism of Action

Elmer M. Cranton, M.D. James P. Frackelton, M.D.

This chapter is adapted from A Textbook on EDTA Chelation Therapy, Second Edition, 2001 edited by Elmer M. Cranton, M.D., Hampton Roads Publishing Company, Charlottesville, Virginia


ABSTRACT: The widely accepted free-radical theory gave us a unified scientific explanation for many diverse benefits following EDTA chelation therapy. Newer concepts of cell-senescence and apoptosis, together with an insight into homocysteine and cholesterol metabolism expand our knowledge, leading to a broader, more comprehensive understanding. The mechanism of action must explain why full benefit occurs several months after chelation is administered and why that improvement persists for months and years thereafter. EDTA has its effect by binding, redistributing and removing metallic ions. Realignment of essential trace elements with augmentation of vital metalloenzymes may be as important as elimination of free radical catalysts and toxic heavy metals.


The use of chelation therapy with intravenous ethylenediaminetetraacetate (EDTA) for the treatment of atherosclerosis is rapidly increasing worldwide. This practice, which began more than four decades ago, accelerates each year. Dozens clinical studies have been published to document safety and effectiveness of intravenous EDTA for treatment of occlusive atherosclerotic arterial disease and age-related degenerative diseases.(1-89) A very important basis for the scientific rational of this therapy is thus the fact that it has been proven effective over and over again in clinical practice. More than one million patients have received more than twenty million infusions with no serious adverse effects--when administered following the approved Protocol. Many years ago reports of kidney damage and other adverse events resulted from excessive doses of EDTA, infused too rapidly (more than 50 mg/Kg/day or infused more rapidly than 16.6 mg/min).

Research with laboratory animals provides further support for the effectiveness of EDTA chelation therapy.(77-83)

There has never been a scientific study of EDTA chelation that did not show effectiveness, although there have been reports in which positive data were erroneously interpreted as negative. Reports of negative or adverse results from EDTA chelation following the currently approved protocol have been either editorial comments and letters to the editor written by opponents of this therapy or seriously flawed attempts to discredit chelation with biased and unscientific interpretation of data--sometimes by cardiovascular surgeons who freely admit their bias.(75,84-89)

In the last ten years, a small cluster of studies has sprouted up in the medical literature purporting to demonstrate that EDTA chelation is not effective in treatment of cardiovascular disease. Although flawed and imperfect, those studies in actuality provide only positive support for chelation. Their negative conclusions are not supported by the data.

EDTA chelation bibliography drcranton.com/edtabib.htm



Whitaker Wellness Institute

Chelation therapy is a highly effective treatment for clearing heavy metals, calcium, and other artery-damaging chemicals from the bloodstream, improving circulation. Although it was first used to treat heavy metal poisoning, chelation has since proven its value for the treatment of heart disease and other circulatory disorders. Chelation has an impeccable record of safety. An FDA safety review spanning 30 years revealed no evidence of significant toxicity. And of over 500,000 patients nationwide treated with chelation therapy using the protocol established by the American College for the Advancement of Medicine, not a single fatality has occurred

A 1993 review of 40 published and 30 unpublished studies involving over 25,000

patients who underwent EDTA chelation demonstrated that 87 percent benefited from this therapy.Brazilian researchers reported the results of EDTA chelation therapy for 2,870 patients



Cardiovascular disease is the number one chronic health problem and cause of death in the U.S.


Dr. Garry Gordon claims that oral chelation prevents or improves most chronic heart problems, and is documented to be more effective than other more expensive treatments involving surgery, angioplasty, etc.


Oral Chelation - The Strongest Natural Treatment for Your Heart, Arteries, Memory, and More




EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc -

EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc -Waters RS, Bryd Waters RS, Bryden NA, Patterson KY, et al. Biol Trace Elem Res 2001; 83:207-221.

These data demonstrate that EDTA chelation therapy results in significantly increased urinary losses of lead, zinc, cadmium, and calcium following EDTA chelation therapy. There were no significant changes in cobalt, chromium, or copper and a retention of magnesium. These effects are likely to have significant effects on nutrient concentrations and interactions and partially explain the clinical improvements seen in patients undergoing EDTA chelation therapy. http://www.findarticles.com/p/articles/mi_m0FDN/is_2_7/ai_85523010

EDTA Intravenous Chelation Demonstrated Effective in Coronary Artery Disease by Electron Beam Tomography by Jonathan Collin, MD

From the Townsend Letter for Doctors & Patients August/September 2002 http://www.townsendletter.com/AugSept_2002/chelation0802.htm





Chelation with EDTA: A Food Additive with Many Remarkable Properties
Ward Dean, MD, clinical study references included, http://www.vrp.com/art/963.asp


EDTA Chelation : The Real "Miracle" Therapy for Vascular Disease

Life Enhancement:



Position Paper on EDTA Chelation Therapy

American College for Advancement in Medicine

It is ACAM's position, as more fully explained in the discussion that ensues, that chelation therapy is a valid and proper course of treatment, based upon scientific rationale, supported by many published clinical studies, and consistent with sound medical practice.





Extreme Health USA, clinical cases and studies show EDTA Oral Chelation effective for cardiovascular problems, http://www.extremehealthusa.com/intro.html

If EDTA Chelation Therapy is so Good, Why Is It Not More Widely Accepted?

Journal of Advancement in Medicine, Volume 2, Numbers 1/2, Spring/Summer 1989, pages 213-226

James P. Carter, MD, DrPH

The answer: money, politics, corruption



A Textbook on EDTA Chelation Therapy Second Edition
Edited by Elmer M. Cranton, M.D.
Foreword by Linus Pauling, Ph.D.

Chelation therapy, based on the intravenous infusion of EDTA, is a highly effective treatment for atherosclerotic cardiovascular disease. Safety and effectiveness are well documented in clinical studies, all of which to date are supportive of this therapy, and there are no studies showing lack of effectiveness. A strong case is made for the use of this safe, efficacious, and inexpensive therapy before resorting to surgery and other risky and invasive treatments.


The NIH Trial of EDTA Chelation Therapy for Coronary Artery Disease


EDTA chelation removes heavy metals and minerals from the blood, such as lead, iron, copper, and calcium, and is approved by the U.S. Food and Drug Administration (FDA) for use in treating lead poisoning and toxicity from other heavy metals. When used as approved by the FDA (at the appropriate dose and infusion rate) for treatment of heavy metal poisoning, chelation with EDTA has a low occurrence of side effects.

there are approximately 12 published descriptive studies and 5 randomized controlled clinical trials regarding the use of EDTA chelation for CAD. Although each descriptive study did report a reduction in angina, they were uncontrolled clinical observations or retrospective data, typically with a small number of participants.

(the results of the randomized trials were similar, improvement but small samples)

A larger study is underway. http://nccam.nih.gov/news/2002/chelation/q-and-a.htm




Los Alamos Scientific Laboratory researchers, EDTA chelation of toxic metals,

J Lab and Clin Med, April, 1954, vol 45, No 4, pp566-570.

The Diagnostic Importance of Glycosuria in Lead Poisoning in Children , Ronald C. Roxburgh and Leonard Haas, Arch Dis Childh, 34-70-3/1959

prolonged courses are without danger to the patient and, in addition, continue

with a variety of circulatory disorders. Among those with peripheral vascular disease and intermittent claudication, 91 percent of these patients experienced "marked" improvement, while 7.6 percent experienced "good" improvement. Of those with ischemic heart disease, 77 percent experienced "marked" improvement in their condition after chelation, while 16.5 percent experienced "good" improvement. Medical Hypotheses, 1988; 27(1): 41-9.

Conditions helped: Cardiovascular disease, Cerebrovascular disease, Diabetic complicationsHeavy metal toxicity, Hypertension, Intermittent claudication, Memory disorders, Peripheral neuropathy Peripheral vascular disease, Slow-healing wounds

A 1999 Australian study examined the effects of chelation therapy with B vitamins on nitric oxide-related endothelial function, or the ability of the arteries to dilate in response to stress. Poor endothelial function is a hallmark of atherosclerotic heart disease and increases the risk of heart attack. In this study, subjects received ten infusions of EDTA combined with B vitamins over a six-week period. Chelation yielded a significant improvement in the ability of arteries to dilate, as measured by blood flow through the forearm. As an added benefit, this combined intravenous therapy also decreased levels of homocysteine, a risk factor for heart attack. Clinical and Experimental Pharmacology and Physiology, 1999; 26(11): 853-6.


Benefits of EDTA Chelation Therapy in Arteriosclerosis: A Retrospective Study of 470 Patients.

C. Hancke, MD and K. Flytile, MD


ABSTRACT: In a retrospective study we report results of EDTA chelation in 470 patients, using a number of parameters, most of them objective. Although the patients acted as their own controls, we observed improvements of 80 to 91%, depending upon the measurement used. Of 92 patients referred for surgical intervention, only 10 required ultimate surgery after or during their chelation therapy, thus saving an estimated 3 million dollars of insurance money. Our experience covers a period of 6 years and we saw no severe side effects or casualties arising from the treatment. We conclude that EDTA chelation therapy is safe, effective and cost saving.

This study included 470 patients with claudication and/or angina pectoris, who received at least 15 treatments. There were 159 women and 311 men. Of these, 206 were older than 69 years, 92 were between 65 and 69, 90 were between 60 and 64, and 82 under 60 years. Diagnosis was verified by systolic ankle-arm blood pressure index (Doppler technique), and by stress test on a treadmill. All were interviewed and examined by a physician before and after treatment.


American College for Advancement in Medicine

Position Paper on EDTA chelation: safety and effectiveness



Clinical experience with EDTA chelation therapy has convinced substantial numbers of licensed physicians in North America that it is a safe and effective treatment for atherosclerotic vascular disease, as it consistently improves blood flow and relieves symptoms associated with the disease in greater than 80% of the patients treated. ACAM's membership of hundreds of doctors nationwide have successfully treated hundreds of thousands of patients with EDTA chelation therapy.


The efficacy of chelation therapy has been clinically demonstrated to thousands of doctors through positive results in hundreds of thousands of cases where this treatment was utilized. One pilot double blind study has already been completed with strongly favorable results.9

9E. Olszewer, F. Sabbag, J. Carter, A Pilot Double Blind Study of Sodium-Magnesium EDTA in Peripheral Vascular Disease, published in J. of Natl. Med. Assn., March, 1990.


CHELATION THERAPY (Heart Disease) www.whale.to/w/Chelation.html

EDTA chelation therapy has brought relief to more than 93% of patients suffering from ischemic heart disease and it can help avoid bypass surgery in 85% of cases.30 When it is given according to established protocols not one serious side effect has been reported. In fact, thousands of anecdotal stories from patients and physicians support the effectiveness and safety of this relatively inexpensive treatment."--- Gary Null www.garynull.com/Documents/Chelation%20Therapy.htm


"Chelation has been used safely over 6 million times in over 400,000 patients in the US alone. Its success rate in improving blood flow in patients with clogged arteries is close to 82%."---Elmer Cranton, author of Bypassing Bypass.

"I routinely see reversal of underlying cardiovascular disease without the risk of expensive surgery."---J Frackelton, M.D.

Heart Surgery Does More Harm Than Good by Julian Whitaker, M.D. www.internetwks.com/pauling/whitaker.html

Dr Edelson www.envprevhealthctratl.com/chelther.htm

Chelation www.medicalmaze.com/hompchel.html

ACAM (chelation doctors) www.acam.org/

Chelation bibliography www.acam.org/biblio.html